

# Targeted-release budesonide for treating primary IgA nephropathy

Information for the public

Published: 20 December 2023

[www.nice.org.uk](http://www.nice.org.uk)

Targeted-release budesonide (Kinpeygo) is available on the NHS. It is a possible treatment for primary immunoglobulin A (IgA) nephropathy in adults when:

- there is a risk of the condition rapidly getting worse
- the urine protein-to-creatinine ratio is 1.5 g/g or more
- it is used alongside optimised standard care, including the highest tolerated licensed dose of an angiotensin-converting enzyme inhibitor or an angiotensin-receptor blocker, unless these cannot be taken.

If you are not eligible for targeted-release budesonide but are already having it, you should be able to continue until you and your doctor decide when best to stop.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS webpage on chronic kidney disease](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Kidney Care UK](#), 01420 541 424
- [Kidney Research UK](#), 0300 303 1100

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5582-4